Mr Shannon Seah is a Singapore-based investment banker focused on covering clients in the Southeast Asian real estate, leisure and lodging sectors, with experience executing landmark equity, debt and mergers and acquisitions (M&A) transactions across the region.

Prior to joining Citi, Mr Seah held roles at other leading financial institutions including UBS Investment Bank and Goldman Sachs, where he began his career in the Tokyo office.

He graduated from NUS with a First Class Honours degree in Physics, during which he completed a research stint at CERN, the European Organization for Nuclear Research. He also earned a degree from Waseda University under the University Scholars Programme Double Degree Programme, graduating as valedictorian. He later attended the University of Cambridge, where he completed an MPhil in Physics with the High Energy Physics research group. 

Ms Lim Hong Yee is Group Chief Pharmacist at NHG Health, Director, Pharmacy Division at Tan Tock Seng Hospital (TTSH) and concurrently President of the 120^th Council of the Pharmaceutical Society of Singapore.

She is currently a member of NHG, TTSH senior management and Clinical Board, and TTSH Drugs and Therapeutics Committee and the Collaborative Prescribing Committee. She is also part of the TTSH Environmental, Social and Governance Council.

Ms Lim played a pivotal role implementing the Outpatient Pharmacy Automation System in TTSH (2015), setting up the framework for Advance Practice pharmacists and collaborative prescribing at TTSH and driving innovation for Allied Health and Pharmacy professionals since the inception of the Centre for Allied Health and Pharmacy Excellence (2019). She was also instrumental in establishing the National Centre of Infectious Diseases Pharmacy (2019) and the Integrated Care Hub Pharmacy (2022). During the pandemic in 2020, she led pharmacy services to support COVID therapeutics access, medication deliveries services ramp up and the medication management pandemic response.

Ms Lim is a recipient of multiple National Day awards including the Public Administration Bronze Award (2024) and the PSS Professor Lucy Wan’s Outstanding Pharmacist Award (2021), one of the highest accolades for pharmacists nationally.   

Mr Peter Govindasamy is Executive Director, Energy Studies Institute at NUS. He holds concurrent appointments at the Ministry of Trade and Industry (MTI), Singapore, as Director-General, International Trade and ASEAN, and Dean, MTI Academy. He is also Adjunct Senior Fellow at the S. Rajaratnam School of International Studies at NTU. Prior to joining MTI, he worked at the Ministry of Foreign Affairs, Singapore.

Mr Govindasmy has more than three decades of experience in public service and has held a range of senior appointments spanning international trade, energy, climate change and sustainable development. Over the course of his career, he has represented Singapore in key bilateral, regional and multilateral negotiations, including at the World Trade Organization (WTO), the United Nations Framework Convention on Climate Change (UNFCCC) and other international platforms. His work has bridged climate action and trade through multilateralism based on the values and principles of the United Nations. 

He was founding member and has been co-Chair of the UNFCCC’s Katowice Committee of Experts on Response Measures since its establishment in 2018. Since 2024, Mr Govindasamy has also co-chaired the negotiation track on the interlinkages between the UNFCCC’s Technology and Finance Mechanisms. At the WTO, he chaired negotiations on domestic regulations in services. He was Chief Negotiator for the Pacific Alliance-Singapore Free Trade Agreement. He has also served as chief negotiator for a number of Singapore’s investment agreements.

He is a Member of the Remaking the Global Trade Project (by Yale University and Fletcher School of Diplomacy and Law), Member of the World Economic Forum Climate Trade Zero initiative and Member of the International Dialogue on Climate and Trade (by Columbia University’s Centre on Global Energy Policy). He is also a member of the ASEAN Dispute Settlement Mechanism Panel.

Dr Creighton Heaukulani is Deputy Director and Principal Data Scientist at Singapore’s Ministry of Health Office for Healthcare Transformation, where he drives initiatives that transform care across the health system and in the community.  

Previously, Dr Heaukulani was Vice President and Executive Director at Goldman Sachs, where he worked as a quant developing Artificial Intelligence trading algorithms in the Securities Division in Hong Kong.

He completed a PhD in Machine Learning at the University of Cambridge in 2015 under the supervision of Professor Zoubin Ghahramani. His specialisation was in Bayesian modelling and inference, and combinatorial stochastic processes.

Dr Heaukulani is an Adjunct Senior Lecturer at the Department of Statistics and Data Science, where he lectures graduate courses on machine learning. He is also training in molecular biology and biotechnology as a graduate researcher at NUS, focusing on molecular biology and cancer epigenetics.

Mr Simran Singh is currently the Chief Executive Officer of Guardant Health AMEA, a precision oncology company that pioneered comprehensive genomic profiling (liquid biopsies). The company has a vast portfolio of diagnostic tests across the continuum of cancer, from late-stage cancer to recurrence monitoring and early cancer detection. Guardant Health AMEA has a presence across 41 countries in Asia, Middle East and Africa.

Prior to Guardant Health, Mr Singh was the Vice President of the Global Medical Devices and Diagnostics Division and Head of Strategic Planning (Asia) for IQVIA, a global contract research organisation where he was instrumental in driving its growth strategy for Asia Pacific and accelerating revenue growth.

Mr Raphael Ho is Chief Executive Officer of EverArc Pharmaceuticals, part of Everest Medicines. He has extensive commercial experience building, leading teams and commercialising assets across emerging markets and the Asia Pacific region.

Mr Ho joined Everest from Convatec where he was the Strategic Initiatives Lead for Emerging Markets driving the transformation of the China and Japan business and expansion into emerging markets. Prior to Convatec, he served as the Asia Pacific General Manager at LianBio, a NASDAQ-listed American biotechnology start-up bringing transformative medicines to patients in China and Asia, as well as the founding General Manager for a Southeast Asia cluster at Amgen.

Prior to Amgen, Mr Ho held various commercial and leadership positions with GlaxoSmithKline (GSK). In his penultimate role based out of GSK’s London headquarters as Global Commercial Director for the Bone / Oncology Business, he oversaw launches in 45 markets across Asia, Middle East and Latin America.

Mr Ho holds Double Masters from Waseda University, Tokyo (Management) and NTU and a B.Appl.Sc. (Hons) in Chemistry, NUS. He has consulted for organisations such as Globant, Nanyang Business School (Healthcare Advisory Board) and BioMedica Gmbh.

Dr Loke Chok Kang leads CSC’s data and Artificial Intelligence (AI) efforts to drive learning analytics for the public service.

Dr Loke’s journey has spanned healthcare, education, finance and government, where he applies data to solve meaningful challenges and improve lives. He is an accredited statistician and advocate for digital innovation who believes that studying statistics and data science is less about mastering formulas and more about training the mind to navigate complexity, ask better questions and lead with purpose. Through mentorships, he continues to inspire graduates to stay curious, embrace change and use their skills to shape a better future for themselves and all. Dr Loke is a graduate of NUS’ then Department of Statistics and Applied Probability (now Department of Statistics and Data Science).